AUG 10, 2026 · PHASE 1/2 TRIAL
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
ClinicalTrials.gov
This is an active clinical trial registry record with no reported results; Phase 1/2 design studying an investigational drug in a molecularly defined population with safety and dose-finding as primary objectives.
Reported
Estimated enrollment300
Phase 1 monotherapy primary outco…Number and type of adverse events
Phase 1 monotherapy primary outco…Recommended Phase 2 Dose